Defects of the`Rb/cyclin D1/p16 pathway' have been shown to play a critical role in the development of virtually all human malignancies assessed. To determine the contribution of G1 phase cell cycle defects to ovarian tumorigenesis, we have examined a panel of normal and tumor ovarian tissues and ovarian cancer cell lines for the expression of Rb, p16 and cyclin D1 proteins. Unlike most types of human cancer whose development involves the loss of either Rb or p16 expression, we observed the coexpression of Rb, p16 and cyclin D1 in 82% of ovarian cancer tissues and cell lines. Furthermore, the growth and cell cycle distribution pro®les of three ovarian cancer cell lines (ES-2, PA-1 and NIH OVCAR-3) that coexpressed Rb and p16, were found to be unaected by adenoviral-mediated overexpression of functional p16 protein, indicating the existence of a defect(s) downstream from p16 in these cells. By contrast overexpression of ectopic p16 in the one ovarian cancer cell line (SK-OV-3) that expressed Rb but lacked p16 protein, resulted in a G1 growth arrest. These data suggest that defects of the`Rb/cyclin D1/p16 pathway', other than the loss of Rb or p16, may play a major role in the development of ovarian cancer. Oncogene (2000) 19, 258 ± 264.
Introduction
Ovarian cancer is the most insidious and lethal of the gynecological malignancies. Unfortunately, attempts to delineate the molecular evolution of ovarian cancers have been hindered by the dierences in the molecular aberrations (as well as clinical characteristics) among the various histopathological subtypes. Recently, several studies have been undertaken to determine the role of defective cell cycle control in the development of ovarian cancer. The`Rb/cyclin D1/ p16 pathway' controls cellular progression through G1 into S-phase of the cell cycle, and appears to be targeted for deregulation in virtually all human malignancies (for a review see Bartek et al., 1997) . The central component of the pathway is the Rb protein, which in its hypophosphorylated (active) state blocks entry into S-phase by binding to E2F (Weinberg et al., 1995 , Weintraub et al., 1992 . Phosphorylation of Rb by cyclin D1/CDK4/6 complexes results in the release of E2F and transit into Sphase (Weinberg et al., 1995) . The binding of p16 to CDK4/6, in turn, inhibits the assembly and maintenance of active cyclin D1/CDK4/6 complexes (Sherr et al., 1994; Serrano et al., 1993) . Thus, abrogation of Rb function and the consequent uncontrolled cellular proliferation appear critical to cancer development. Multiple human tumors undergo the direct inactivation of Rb, usually as a result of mutation, rearrangement or deletion of the gene (for a review see Sellers and Kaelin, 1997) . In cancers where Rb protein is expressed, defects of other loci integral to the`Rb/cyclin D1/p16 pathway' have frequently been observed that serve to override Rb function. The most common defect of this type is the loss of p16 expression with or without the accompanying overexpression of cyclin D1 protein (for reviews, see Sclafani et al., 1996; Palmero et al., 1997) . Because the loss of either Rb or p16 activity is sucient to permanently deregulate the G1/S-phase transition, their joint inactivation is extremely rare in human cancers (Otterson et al., 1994; He et al., 1995; Geradts et al., 1995) .
Alterations of the Rb gene are relatively infrequent in ovarian cancers (Li et al., 1991; Liu et al., 1994) as is the loss of Rb protein expression. Indeed, immunohistochemical analysis of ovarian tumors indicates that 71 ± 86% of ovarian carcinomas and 100% of both tumors of low malignant potential and benign lesions express Rb protein (Taylor et al., 1995; Nieman et al., 1998) . Studies aimed at identifying potential defects in other components of the`Rb/ cyclin D1/p16 pathway' in ovarian tumors have focused primarily upon the structural and expression analyses of either the cyclin D1 or p16 genes, respectively. Cyclin D1 protein overexpression occurs in approximately 26 ± 32% of primary ovarian tumors (Hung et al., 1996; Worsley et al., 1997; Sui et al., 1999) and appears to be related to histopathological subtype. Aberrations of the p16 gene are far less common, however. The p16 gene, which localizes to chromosome 9p21, is inactivated at a high frequency in a variety of tumors that, like the majority of ovarian cancers, express endogenous Rb protein. The major mechanisms of p16 inactivation in sporadic tumors include the homozygous deletion or methylation of the gene, and seldom mutation (for a review see Serrano, 1997) . Indeed, several groups have reported frequencies of loss of heterozygosity on chromosome 9p ranging from 30 ± 48% in ovarian cancers with the consensus minimally deleted region encompassing the p16 locus at 9p21 (Chenevix-Trench et al., 1994; Osborn and Leach, 1994; Campbell et al., 1995; Schultz et al., 1995) . However, in those cases where the remaining homologue was sequenced, none were found to harbor inactivating mutations of p16 (Chenevix-Trench et al., 1994; Campbell et al., 1995; Schultz et al., 1995) . Additional SSCP-based studies of the p16 gene by Schuyer et al. (1996) yielded no evidence of inactivating mutations in 37 primary ovarian tumors. Similarly, homozygous deletions of the p16 gene have rarely been detected in ovarian tumors, at frequencies ranging from 0 ± 17% (Campbell et al., 1995; Schultz et al., 1995; Radabaugh et al., 1995; Marchini et al., 1997; Kanuma et al., 1997; Shih et al., 1997) .
In the absence of a high frequency of deletions or mutations, several groups have looked for evidence of transcriptional silencing of the p16 gene via 5' CpG island methylation. Three independent studies found no evidence of p16 hypermethylation in a total of 115 ovarian tumors and three ovarian cancer cell lines (Shih et al., 1997; Marchini et al., 1997; Ryan et al., 1998) . By contrast, McCluskey et al. (1999) and Milde-Langosch et al. (1998) identi®ed p16 hypermethylation in 2/29 and 12/94 ovarian tumors, respectively. Notably, the majority of tumors that showed p16 hypermethylation in the latter two studies were of the endometriod or mucinous histopathological sub-types. This suggests that the loss of p16 expression may be a characteristic of certain subtypes of ovarian tumor.
Consistent with the low incidence of p16 gene alterations, the majority of ovarian tumors express p16 protein. Immunohistochemical studies by Dong et al. (1997) and Milde-Langosch et al. (1998) detected the expression of p16 protein in 89 and 80% of ovarian tumors, respectively. Furthermore, Marchini et al. (1997) detected p16 protein expression in 74% of ovarian tumors by Western blot analysis. The immunohistochemical studies, in keeping with the methylation studies above, reported a positive correlation between the expression of p16 and the non-mucinous histopathological subtypes of ovarian tumors.
None of the above studies of p16 gene structure and expression included a parallel analysis of Rb protein expression. However, owing to the reportedly low frequency of Rb inactivation in ovarian tumors (Li et al., 1991; Liu et al., 1994) , it is likely that the majority of tumors in those studies expressed Rb. This would, in turn, suggest that the coexpression of Rb and p16 is common in ovarian cancer, thereby raising questions as to the nature and extent of`Rb/cyclin D1/p16 pathway' defects in ovarian cancer cells.
We present here an analysis of normal and tumor ovarian tissues and ovarian cancer cell lines for the expression of all three of the major G1 regulatory proteins ± Rb, p16 and cyclin D1. Contrary to the loss of either Rb or p16 often observed in many cancer types, we report that a high frequency of ovarian cancers coexpress Rb, p16 and cyclin D1 proteins, with the majority overexpressing p16 protein.
In addition, we present functional studies utilizing ovarian cancer cell lines that reveal the contribution to ovarian cancer development of defects in the`Rb/ cyclin D1/p16 pathway' other than the loss of Rb or p16 expression.
Results

Coexpression of Rb, p16 and cyclin D1 in ovarian cancers
A panel of six ovarian cancer cell lines was examined for the expression of Rb, p16 and cyclin D1 by Western blot analysis. With regard to Rb protein expression, we interpreted the detection of both the hyperphosphorylated and hypophosphorylated states of Rb protein to indicate a functional protein, since mutations of Rb in human cancers have been found to result in defects in the expression and/or phosphorylation of the Rb protein (for a review see Sellers and Kaelin, 1997) .
Consistent with previous observations of a low frequency of Rb inactivation in ovarian cancers (Li et al., 1991; Liu et al., 1994) , we detected the expression of Rb protein in ®ve of the six ovarian cancer cell lines (Figure 1 ). Cyclin D1 protein was expressed by all six of the cell lines, four of which (Caov-3, ES-2, PA-1 and SW626) showed overexpression relative to a positive control, MCF-7 ± a breast cancer cell line that shows approximately tenfold overexpression of cyclin D1 protein ( Figure  1 ). p16 protein was expressed by ®ve of the six cell lines, four of which coexpressed Rb protein ( Figure  1 ). Of the ®ve p16-positive cell lines, three (Caov-3, ES-2 and NIH OVCAR-3) expressed exceptionally high levels of p16 protein, marginally exceeding that of HBL-100 ± a SV40-transformed breast epithelial cell line that lacks functional Rb (owing to the binding of SV40 Large T Antigen) and overexpresses p16 protein. The remaining two p16-positive cell lines (PA-1 and SW626) expressed moderate and low levels of p16 protein, respectively, relative to HBL-100. Only one ovarian cancer cell line, SK-OV-3, coexpressed Rb and cyclin D1 proteins, and lacked detectable p16 expression, consistent with the report of a homozygous deletion at the p16 locus in this cell line (Gemma et al., 1996) . Our analysis therefore revealed that four of six transformed ovarian cancer Figure 1 Expression of Rb, p16 and cyclin D1 proteins in ovarian cancer cell lines. Extracts were prepared from logarithmic phase cultures of the indicated ovarian cancer cell lines and equal amounts of protein subjected to SDS ± PAGE. Following protein transfer, the membranes were probed with antibodies to Rb, p16 and cyclin-D1, as indicated to the right of the ®gure. The MCF-7 cell line acted as a positive control both for the expression of Rb and cyclin D1, and the HBL-100 cell line acted as a positive control for the expression of p16 cell lines were able to proliferate in an unregulated manner despite the presence of both Rb and p16 negative regulatory proteins.
To determine if the cell line data was representative of primary ovarian tumors, we analysed the expression of Rb, p16 and cyclin D1 proteins in extracts derived from two matched pairs of normal and tumor ovarian tissue extracts, and nine unmatched ovarian tumor tissue extracts. Consistent with the cell line data, the vast majority of the ovarian tumors (10/11) coexpressed Rb, p16 and cyclin D1 proteins (Figure 2 ). Of these ten tumors, seven (including the two with matched normal tissue counterparts) expressed abnormally elevated levels of p16 protein relative to the two normal tissue controls ( Figure 2 ). The remaining three expressed levels of p16 protein that were equivalent to the low levels present in the two normal tissues (Figure 2 ). Only one tumor (COV-1T) lacked detectable p16 protein expression in the presence of Rb and cyclin D1 protein expression (Figure 2 ). Overexpression of cyclin D1 protein was observed in just three of the 11 Rb-positive tumors assessed. Notably, these three tumors also overexpressed p16 protein ( Figure 2 ). These data strongly suggest that ovarian tumor development, unlike that of most human malignancies rarely involves the loss of either Rb or p16 expression. However, the evidence for the universal role of`Rb/cyclin D1/p16 pathway' deregulation in human tumorigenesis suggested to us that these ovarian cancer cells may have harbored a defect(s) in cell cycle regulation that was not revealed by the qualitative analysis of the levels of Rb, p16 and cyclin D1 proteins. A defect in the endogenous p16 protein, for example, may have rendered it inactive as an inhibitor of cell cycle progression. Alternatively, the presence of defects in other components of thè Rb/cyclin D1/p16 pathway' may have left the cells insensitive to the inhibitory actions of functional p16. To address these possibilities we employed a recombinant adenovirus, Ad-p16, to investigate the sensitivity of four ovarian cancer cell lines to high levels of functional p16 protein.
Ovarian cancer cells that coexpress endogenous Rb and p16 proteins are insensitive to adenoviral-mediated overexpression of functional p16 protein Three of the cell lines chosen for infection with Ad-p16 expressed p16 protein at moderate (PA-1) and high (ES-2 and NIH OVCAR-3) levels, respectively, in addition to Rb and cyclin D1. The fourth cell line, SK-OV-3, expressed Rb and cyclin D1 but lacked p16 expression. We included two control cell lines in our analysis: MCF-7, a Rb-positive breast cancer cell line that is homozygously deleted for the p16 gene and arrests in G1 in response to adenoviral-mediated p16 expression (Craig et al., 1998) ; and HBL-100, a SV40-transformed breast epithelial cell line, that lacks functional Rb protein, overexpresses p16 protein, and is refractory to adenoviral-mediated p16 expression (Jin et al., 1995) .
Prior to infection with the Ad-p16 construct, we determined the transduction eciency of a control Figure 2 Expression of Rb, p16 and cyclin D1 proteins in normal and tumor ovarian tissues. Extracts were prepared from frozen ovarian tissues and subjected to SDS ± PAGE. Following protein transfer, the membranes were probed with antibodies to Rb, p16 and cyclin D1, as indicated to the right of the ®gure. The membrane initially probed with p16 and D1 was then reprobed with an antibody to actin as a loading control. Normal and tumor tissues were designated by`N' and`T' suxes, respectively Figure 3 Eect of adenoviral-mediated overexpression of p16 protein upon ovarian cancer cell lines. Logarithmic phase cultures of ovarian cancer cell lines that either coexpressed Rb and p16 (ES-2, NIH OVCAR-3 and PA-1) or expressed Rb but lacked p16 (SK-OV-3) were infected with the Ad-p16 recombinant adenovirus at a moi of 50 or mock-infected. HBL-100 and MCF-7 breast cell lines acted as p16-insensitive and p16-sensitive controls, respectively. Following incubation at 378C for 42 h, the cells were harvested for cell cycle distribution analysis by FACS. Ectopic p16 overexpression in the p16-negative SK-OV-3 cells resulted in a profound accumulation of cells in G1, as indicated by the increase in the left hand peak (A), but did not signi®cantly aect the cell cycle distribution pro®le of the ES-2, PA-1 and NIH OVCAR-3 cells that coexpressed Rb and p16 proteins (B). In the case of NIH OVCAR-3, the major aneuploid population of cells as well as a minor subpopulation of diploid cells (shown in solid black), were equally unaected by p16 overexpression adenoviral vector that lacked the p16 gene. Each of the cell lines were infected at a range of multiplicities of infection (moi), with a recombinant adenovirus, Ad-GFP, that expressed green¯uorescent protein. A moi of 50 resulted in a transduction eciency of 495% in all of the cell lines examined, with no evidence of a cytopathic eect upon the host cells. Logarithmic phase cultures of each of the cell lines were then infected at a moi of 50 with Ad-p16. As controls, parallel cultures were also mock-infected and infected at a moi of 50 with the control virus, Ad-GFP. After 42 h at 378C, the cells were harvested and analysed both for cell cycle distribution by FACS, and the expression of p16 and several other cell cycle regulatory proteins by Western blot. Following infection with the control virus, Ad-GFP, all of the cell lines showed the same cell cycle distribution pro®le as the mock-infected cells (data not shown) indicating that the adenoviral vector lacking the p16 gene had no eect upon the growth characteristics of the cells.
Ad-p16-infection of each of the cell lines resulted in very high levels of p16 protein expression ( Figure 4) . As expected the overexpression of p16 in the MCF-7 control cells resulted in a signi®cant G1 block. Likewise, the p16-negative SK-OV-3 ovarian cancer cells accumulated in G1 and ceased to proliferate (Figure 3 ). By contrast, the growth and cell cycle distribution of ES-2, NIH OVCAR-3 and PA-1 cells (which expressed endogenous Rb and p16 proteins) were not aected by ectopic p16 protein overexpression, as was the case for the p16-insensitive HBL-100 control cells (Figure 3) . Furthermore, these three ovarian cancer cell lines and the HBL-100 cells retained their insensitivity to even higher levels of p16 following infection with the Ad-p16 construct at a moi of 150 (data not shown).
Western analysis of cell cycle regulatory protein expression supported the cell cycle distribution data (Figure 4) . The p16-sensitive SK-OV-3 and MCF-7 (control) cell lines underwent a shift in the expression of Rb protein to the fully active hypophosphorylated state following infection with Ad-p16, consistent with their cessation of growth. Notably, we observed a decrease in the total level of Rb protein, consistent with the ®ndings of Fang et al. (1998) who previously demonstrated that overexpression of p16 appears to down-regulate Rb expression. In addition, both cell lines underwent a signi®cant decrease both in the expression of cyclin A, which is ordinarily expressed upon entry into S phase and maintained throughout G2/M, and the mitotic phase cyclin B1 (Figure 4) . The ability of ectopically overexpressed functional p16 protein to restore the Rb-mediated G1 block in both SK-OV-3 and MCF-7 suggested that the loss of p16 expression was the rate-limiting defect of the`Rb/ cyclin D1/p16 pathway' in these cancer cell lines. Indeed, in the case of MCF-7, the restoration of p16 protein expression proved sucient to override the eects of the abnormally elevated levels of endogenous cyclin D1 protein.
In contrast, neither the Ad-p16-infected ovarian cancer cell lines, ES-2, NIH OVCAR-3 and PA-1, nor the breast epithelial cell line, HBL-100, showed any signi®cant changes in the expression of the cell cycle regulatory proteins assessed, consistent with their unperturbed cellular proliferation (Figure 4) . One notable dierence between the three p16-insensitive ovarian cancer cell lines was the eect of the ectopic p16 overexpression on the phosphorylation status of the Rb protein. The ES-2 and NIH OVCAR-3 cells expressed an almost identical ratio of hyperphosphorylated to hypophosphorylated Rb in the mockinfected versus Ad-p16-infected cells, with evidence of a barely detectable reduction in the amount of hyperphosphorylated Rb protein in the Ad-p16 infected NIH OVCAR-3 cells (Figure 4 ). This suggested that the overexpressed p16 protein had little inhibitory eect upon the kinase activity of CDK4/6 proteins in these Figure 4 Eect of adenoviral-mediated overexpression of p16 protein upon the expression of cell cycle regulatory proteins in ovarian cancer cell lines. The ovarian cancer cell lines ES-2, NIH OVCAR-3 and PA-1 (that coexpressed Rb and p16 proteins) and SK-OV-3 (that expressed Rb but lacked p16) were infected with Ad-p16 or mock-infected as described in the legend to Figure 3 . The breast cell lines, HBL-100 and MCF-7, were also included as p16-insensitive and p16-sensitive controls, respectively. Following infection, the cells were harvested and their extracts analysed for the expression of several cell cycle regulatory proteins two cell lines. By contrast, the PA-1 cells underwent a more marked shift to the predominantly hypophosphorylated form of Rb protein in the Ad-p16-infected cells as did the HBL-100 control cells (Figure 4 ). This suggested that the p16 protein was able to bind to the CDK4/6 kinases in these cell lines, resulting in a virtually complete inhibition of Rb phosphorylation by cyclin D1/CDK4/6 complexes. In the case of HBL-100, the p16-insensitivity can be explained by the fact that Rb is functionally compromized due to the binding of SV40 Large T Antigen. Although less pronounced than that observed in the p16-sensitive SK-OV-3 and MCF-7 cell lines, all three of the p16-insensitive ovarian cancer cell lines (in addition to the HBL-100 control cell line) showed a discernable decrease in the total level of Rb protein expressed following ectopic p16 overexpression. This observation, again supports the role of p16 as a negative regulator of Rb expression as proposed by Fang et al. (1998) .
The ®nding that ovarian cancer cell lines that coexpress endogenous Rb and p16 proteins are insensitive to ectopic overexpression of p16 suggests that they are defective in cell cycle regulation downstream from p16. The dierential eects of ectopic p16 expression upon Rb phosphorylation status further implies the existence of defects at more than one level of the`Rb/cyclin D1/p16 pathway' in dierent ovarian cancer cell lines that renders them refractory to the presence of functional p16 protein.
Discussion
The majority of human cancers show a qualitative alteration in the expression of one or more of the components of the`Rb/cyclin D1/p16 pathway'. This usually takes the form of the loss of either Rb or p16 expression (Otterson et al., 1994; He et al., 1995; Geradts et al., 1996) . These ®ndings have led to the view that the loss of Rb-mediated regulation at the G1/ S checkpoint is critical to the development of human malignancy.
Studies of ovarian tumors and cell lines have, todate, focused upon the identi®cation of abnormalities within individual genes of the`Rb/cyclin D1/p16 pathway', in isolation. However, since the pathway, appears to act as a single target for deregulation during tumorigenesis, we have investigated the expression of the three major G1 checkpoint regulatory proteins, Rb, p16 and cyclin D1, in a panel of ovarian tumor tissues and cell lines. In addition, protein expression in the tumors was directly compared to that of normal ovarian tissues, enabling the detection of tumorspeci®c abnormalities in the levels of the three proteins.
We found that ten of eleven ovarian tumors coexpressed Rb, p16 and cyclin D1 proteins, while one tumor coexpressed Rb and cyclin D1 but lacked p16 protein expression. Furthermore, seven of the 11 Rb-positive tumors overexpressed p16 protein, relative to normal ovarian tissue controls. These data support the high frequency of p16 expression in ovarian tumors observed by Dong et al. (1997) , Milde-Langosch et al. (1998) and Marchini et al. (1997) . The expression of both Rb and p16 proteins in four of the six ovarian cancer cell lines further indicated that the transformation of ovarian cancer cells frequently occurs in the absence of the loss of either one of these two negative regulators of the G1 checkpoint. These data were intriguing because, as mentioned above, the majority of human tumors assessed to-date, exhibit the loss of either Rb or p16 expression (Otterson et al., 1994; He et al., 1995; He et al; Geradts et al., 1996) . Therefore, the ®nding of the coexpression of Rb and p16 in the large majority of ovarian tumors raises the question as to whether defects in G1 cell cycle regulation actually contribute to the development of most ovarian cancers.
To address this question, we investigated the eect of high levels of functional p16 protein (expressed from a recombinant adenovirus) upon the growth of ovarian cancer cell lines that either coexpressed Rb and p16 (ES-2, NIH OVCAR-3 and PA-1) or expressed Rb but lacked the p16 gene (SK-OV-3). The SK-OV-3 cell line showed a signi®cant G1 arrest in response to ectopic p16 overexpression. Thus, in these cells, the replacement of p16 expression appeared sucient to inhibit cyclin D1/CDK4/6 kinase function and restore the Rbmediated G1/S block. This was consistent with a previous report of p16-induced growth inhibition in the SK-OV-3 cell line by Wolf et al. (1999) . Similarly, Craig et al. (1998) reported that adenoviral-mediated p16 overexpression resulted in G1 arrest coincident with a decrease in DNA synthesis in a panel of Rbpositive human cancer cell lines that lacked p16 protein. By contrast, all three of the ovarian cancer cell lines in our study that coexpressed Rb and p16 were completely refractory to the overexpression of p16 and continued to grow unabated. This insensitivity to adenoviral-mediated p16 overexpression has previously been reported only in human cancer cell lines that lack Rb and express p16 protein (Craig et al., 1998) . Thus it appeared that the ES-2, NIH OVCAR-3 and PA-1 cell lines harbored a defect of the`Rb/cyclin D1/p16 pathway' that was downstream from p16, resulted in abrogation of G1/S checkpoint function, and which, importantly was not revealed by the analysis of the levels of Rb, p16 and cyclin D1 proteins in these cells.
In contrast to our ®ndings of insensitivity to p16 overexpression, Wolf et al. (1999) have recently reported that an ovarian cancer cell line (OVCA 420) coexpressing Rb and p16 undergoes growth inhibition in response to adenoviral-mediated p16 overexpression, and concluded that sensitivity to high levels of ectopic p16 is independent of the endogenous p16 status of cells. However, no data demonstrating endogenous p16 expression by this cell line was presented (Wolf et al., 1999) . Furthermore, Fang et al. (1998) have presented clear evidence that OVCA 420 cells do not express p16. Therefore, the signi®cance of the experiments carried out in OVCA 420 cells for evaluating the relationship between endogenous p16 status and sensitivity to p16 overexpression is dicult to interpret unambiguously. Nevertheless, the results we present here clearly indicate that the retention of p16 expression is accompanied by loss of sensitivity to growth inhibition by this protein, suggesting the presence of a novel cell cycle defect(s) associated with the development of malignancy.
The dierential eect of functional p16 overexpression upon the Rb protein phosphorylation state of the p16-insensitive cell lines, ES-2, NIH OVCAR-3 and PA-1, suggested the existence of more than one type of possible defect downstream of p16 in these cells. In the cases of ES-2 and NIH OVCAR-3, the expression of ectopic p16 did not appear to signi®cantly aect the proportion of hyperphosphorylated and hypophosphorylated states of the endogenous Rb protein. This suggested the inability of the ectopic p16 to completely inhibit cyclin D1/CDK4/6 complex kinase activity and raised the possibility that these cells might contain an alternative form of CDK4 and/or CDK6 that was insensitive to inhibition by p16. A mutation that results in an arg to cys transition in CDK4 and renders it unable to be bound and inhibited by p16 has been reported in familial melanomas (Wolfel et al., 1995; Zuo et al., 1996) . However, we found that neither ES-2 nor NIH OVCAR-3 cells harbored this mutation (data not shown). This leaves open the possibility however, that there may be other mutations within the CDK4 or CDK6 genes that similarly disrupt or ablate p16 binding in ovarian cancer cells. In the case of the ES-2 cell line, such kinase defects may be further compounded by the abnormally high endogenous cyclin D1 protein expression.
The cell line, PA-1, showed a signi®cant loss of Rb phosphorylation in response to ectopic p16 overexpression. From this we concluded that the ectopic p16 protein was able to successfully inhibit cyclin D1/ CDK4/6 kinase activity, but that the hypophosphorylated (active) form of Rb was unable to eect a G1 block. The fact that the endogenous Rb protein expressed by PA-1 cells was of the correct size, capable of being phosphorylated, and coexpressed with cyclin D1, argued that it was functional. This being the case, a defect downstream of Rb that rendered the latter ineective, such as a mutation in E2F, might provide a more likely explanation for the absence of a G1 arrest in Ad-p16-infected cells. E2F mutations have not been detected in human cancer cells although ampli®cation and elevated transcription of the gene was detected in an erythroleukemia cell line (Saito et al., 1995) . Deregulation of cyclin E has also been shown to overcome Rb function. Indeed, Hinds et al. (1992) have shown that the Rb block to proliferation can be overcome by overexpression of cyclin E protein in Saos-2 cells. Further, Gray-Bablin et al. (1996) have proposed a role for cyclin E overexpression in overriding Rb function in breast cancer cells. However, it appears unlikely that this mechanism is responsible for the p16 insensitivity in PA-1 cells since they do not express abnormally elevated levels of cyclin E protein (Figure 4 and data not shown). Finally we cannot rule out the possibility that the deregulated cell cycle control exhibited by the PA-1 cells is independent of a defect within the`Rb/ cyclin D1/p16 pathway'.
The demonstration of p16 insensitivity in ovarian cancer cell lines that coexpress Rb and p16 strongly implies the existence of an as yet unidenti®ed G1 pathway defect(s) in these cells. These cell line data coupled with the frequent coexpression of Rb and p16 in primary ovarian tumors suggest that defects of this nature might make a substantial contribution to the development of ovarian cancer. Furthermore, the coexpression of Rb and p16 proteins is not unique to ovarian cancers. Indeed, it has been identi®ed in 16 ± 24% of lung cancers (Geradts et al., 1995; Sakaguichi et al., 1996) , 37% of bladder cancers, 84% of colon cancers (Geradts et al., 1995) and 25 ± 57% of primary breast tumors (Geradts et al., 1995 (Geradts et al., , 1996 Gray-Bablin et al., 1996) . In addition, we have found that a subgroup of breast cancer cell lines that coexpress Rb and p16 are also refractory to adenoviral-mediated p16 overexpression (Todd et al., manuscript in preparation). These data strongly imply that G1 defects ± that do not include the loss of either Rb or p16 expression ± may play a greater role than has thus far been appreciated in the tumorigenesis of multiple human malignancies. This being the case, the results of our in vitro adenoviral-p16 studies may prove of some future clinical relevance as they suggest that tumors that coexpress Rb and p16 may be unresponsive to p16 gene therapy.
Materials and methods
Ovarian cell lines and tissues
Six ovarian cancer cell lines were used in this study. Caov-3, ES-2, PA-1, SK-OV-3 and SW626 were obtained from the ATCC, and NIH OVCAR-3 was obtained from the University of Colorado Cancer Center Tissue Culture Core Facility. Caov-3 was cultured in DME medium plus 0.45% glucose, 1 mM sodium pyruvate, 2 mM L-glutamine and 10% serum. SW626 was cultured in Leibovitz's L-15 medium plus 2 mM L-glutamine and 10% serum. ES-2 and SK-OV-3 were cultured in McCoy's 5a medium plus 2 mM L-glutamine and 10% serum. NIH OVCAR-3 was cultured in OPTI-MEM medium plus 2 mM L-glutamine and 3.5% serum. PA-1 was cultured in MEM medium plus 0.1 mM non-essential amino acids, 2 mM L-glutamine and 10% serum.
Two matched pairs of frozen normal and tumor ovarian tissues and nine unmatched frozen ovarian tumor tissues were obtained from the University of Colorado Tissue Procurement Core (Denver, CO, USA). Eight of the tumors were epithelial carcinomas, two were benign epithelial tumors, and one was a teratoma.
Antibodies
The a-p16, a-Rb and a-cyclin D1 antibodies were obtained from Oncogene, Pharmingen and Upstate Biotechnology, respectively. The horseradish peroxidase-conjugated secondary antibodies were obtained from Bio-Rad.
Adenoviral expression constructs
The construction of the recombinant adenovirus, Ad-p16, is described in Jin et al. (1995) and was kindly provided by Introgen Therapeutics (Houston, TX, USA). The Ad-GFP recombinant adenovirus was a gift from Dr Jerome Schaack (Department of Microbiology, University of Colorado Health Sciences Center, Denver, CO, USA).
Protein isolation and Western blot analysis
Ovarian cancer cell lines were harvested at sub-con¯uence with PBS/1 mM EDTA, and washed twice in PBS. Following centrifugation, the cells were resuspended in Laemmli sample buer (Laemmli, 1970) , boiled for 4 min and sheared through a 26-gauge syringe needle. Individual pieces of frozen normal and tumor ovarian tissues, each weighing approximately 0.1 ± 0.2 g, were crushed to a ®ne powder under liquid nitrogen, lysed in boiling Laemmli sample buer (Laemmli, 1970) for 5 ± 7 min and sheared through a 26-gauge needle.
Approximately 50 mg of each protein extract were subjected to SDS ± PAGE (Laemmli, 1970) and electrophoretically transferred to nitrocellulose membranes, (Schleicher and Schuell) for 45 min at 0.45 A. Immunodetection was performed using the enhanced chemiluminescence (ECL) kit (Amersham) according to the manufacturers' instructions.
Adenoviral infection of ovarian cancer cell lines
Ad-p16 and Ad-GFP viral supernatants were diluted in culture medium to give the desired concentration and added to logarithmic phase monolayer cell cultures growing in 10 cm plates. Following incubation at 378C for 42 h, half of the cells were stained with propidium iodide (Krishan et al., 1975) and analysed for cell cycle distribution (at the University of Colorado Cancer Center Flow Cytometry Core, Denver, CO, USA) while the remainder were used for protein isolation and analysis of cell cycle regulatory protein expression.
